Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Conditions
Interventions
Lumateperone 42 mg
Placebo
Locations
43
United States
Clinical Site
Little Rock, Arkansas, United States
Clinical Site
Bellflower, California, United States
Clinical Site
Cerritos, California, United States
Clinical Site
Culver City, California, United States
Clinical Site
Garden Grove, California, United States
Clinical Site
Lemon Grove, California, United States
Start Date
July 8, 2021
Primary Completion Date
July 25, 2024
Completion Date
August 7, 2024
Last Updated
November 7, 2024
NCT06894212
NCT04226898
NCT05240976
NCT06745479
NCT07455929
NCT05304767
Lead Sponsor
Intra-Cellular Therapies, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions